rAAt (dermatological) Arriva/ProMetic.

Article Details

Citation
Copy to clipboard

Brown WM

rAAt (dermatological) Arriva/ProMetic.

Curr Opin Mol Ther. 2006 Feb;8(1):69-75.

PubMed ID
16506528 [ View in PubMed
]
Abstract

Arriva Pharmaceuticals Inc and ProMetic Life Sciences Inc are developing a gel formulation of recombinant alpha1-antitrypsin (rAAT). The therapy, as a topical formulation, is in phase II clinical trials for the potential treatment of atopic dermatitis and severe dermatological disorders. rAAT is also under preclinical investigation for the potential treatment of other inflammatory skin conditions, including psoriasis, as well as for otitis media.

DrugBank Data that Cites this Article

Drugs